Hennessey reported a relationship with AbbVie. Source Reference: Li Q, et al "Thyroid function reference intervals by age, sex, and race: a cross-sectional study" Ann Intern Med 2025; DOI ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is not well aligned with FDA’s authority to regulate drug safety and efficacy ...

Instead, it allowed for a blood sample to be inoculated with a radioactive form of thyroid hormone ... The creation of AbbVie In 2011, Abbott announced it was to separate into two leading ...

AbbVie will pay Danish antibody specialist Genmab ... for Tepezza (teprotumumab), an antibody for the treatment of thyroid eye disease. Its biggest success to date by a long margin is the alliance ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company's stock ...

An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

AbbVie Q1 sales rose 8.4% to $13.34 billion, and adjusted EPS grew 6.5% to $2.46, beating Wall Street estimates. Skyrizi sales jumped 70.5% to $3.43 billion, and Rinvoq sales climbed 57.2% to $1. ...

These two policies could have major impacts on AbbVie, Lilly, and Johnson & Johnson. Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Shares of AbbVie (ABBV) appear to be overbought. The recent move higher may pause or even end. Get stock picks, daily rankings, and pro-level trading tools in one powerful platform—now 60% off ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a $16.5 million outlay. Eli Lilly and Boehringer Ingelheim’s ...